BioSpace News Archive

Cash and cash equivalents and marketable securities as of September 30, 2017 were $43.8 million, compared to $64.1 million as of December 31, 2016.

Novavax reported a net loss of $44.6 million, or $0.15 per share, for the third quarter of 2017, compared to a net loss of $66.3 million, or $0.24 per share, for the third quarter of 2016.

Groundbreaking ceremony spotlights local partnerships and the company’s dedication to serving expanding global business. [08-November-2017] LIBERTYVILLE, Ill., Nov. 8, 2017 /PRNewswire/ -- Hollister Incorporated, a global medical device manufacturer, today held a groundbreaking ceremony signifying the start of construction on a manufacturing plant in the K

During the third quarter, the Company announced positive top-line results from its Phase 3 Study 1 of ZX008 in patients with Dravet syndrome.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 13, 2017 at 11:00 a.m. ET.

Revenue of $802.9 million increased 10.5%, or 9.9% in constant currency, compared to the prior year period. Excluding the net impact of the Cynosure acquisition and blood screening divestiture, fourth-quarter revenue increased 5.0%, or 4.4% in constant currency.

As reported on November 3, 2017, the Company received a delisting determination letter from the Staff of the Listing Qualifications Department (the"LQ Staff”) of The Nasdaq Stock Market, Inc.

Cash, cash equivalents, and marketable securities at September 30, 2017, were $295.7 million, compared to $199.9 million at September 30, 2016.

The company reported a net loss of approximately $2.7 million, or $0.12 per share, for the third quarter of 2017, compared to a net loss of approximately $5.3 million, or $0.29 per share, for the third quarter of 2016.

Net loss was $10.0 million, or $0.50 per common share (basic and diluted), for the quarter ended September 30, 2017.